HemoSonics, LLC has been honored as #453 on the 2024 Deloitte Technology Fast 500, recognizing its significant revenue growth over the past three years. The company, focused on acute bleeding management, was one of eight North Carolina firms included in this prestigious ranking. This award highlights the company’s dedication and success in advancing healthcare technology.
HemoSonics, LLC, a Durham-based medical device company specializing in acute bleeding management, has been recognized in the Deloitte Technology Fast 500™ list for 2024. Ranking at 453, HemoSonics stands out among the most rapidly expanding technology companies across North America. This prestigious award celebrates organizations for their fiscal year revenue growth between 2020 and 2023, during which HemoSonics successfully more than doubled its revenue. Notably, it is among only eight companies from North Carolina that received this acknowledgment.
The Deloitte Technology Fast 500 is a well-regarded annual ranking that highlights the fastest-growing companies in various sectors including technology, media, telecommunications, life sciences, fintech, and energy tech. This program recognizes growth based on revenue increases, showcasing companies that have demonstrated remarkable business acumen and resilience over a three-year period. With less than 1% of over 800,000 privately held firms in the U.S. receiving this recognition, being named to this list is a significant achievement for any company.
In conclusion, HemoSonics’ placement at #453 on the Deloitte Technology Fast 500 list emphasizes its remarkable growth trajectory and industry impact. This recognition not only reflects the company’s success in acute bleeding management but also positions it as a leader in innovative medical solutions within the North American healthcare market. The accolade signifies a commitment to improving patient outcomes through advanced technology.
Original Source: www.galvnews.com
Leave a Reply